Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAT Extension Study in Type 1 Diabetes Mellitus
NCT01661192Phase 2Completed
- Sponsor
- Rabin Medical Center
- Start
- Jan 2013
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpha-1-proteinase inhibitor in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Rabin Medical Center. Primary endpoints: Safety and tolerability of AAT in terms of adverse events and serious adverse events at 36 months and Safety and tolerability of the AAT in terms of laboratory values at 36 months. Started Jan 2013; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01661192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661192.